Beyond its well-documented effects on cancer and inflammation, Angelicin, a furanocoumarin, is revealing promising capabilities in the fight against infectious diseases. NINGBO INNO PHARMCHEM CO.,LTD. is actively investigating these critical antimicrobial and antiviral properties.

Angelicin has demonstrated significant antimicrobial activity, particularly against oral pathogens like Porphyromonas gingivalis (P. gingivalis). Studies have shown that Angelicin can effectively inhibit the formation and thickening of P. gingivalis biofilms, a key factor in periodontal disease. Notably, its efficacy in reducing bacterial viability and its low cytotoxicity towards human cells make it a potentially valuable agent for therapeutic interventions in oral health. This antimicrobial action suggests Angelicin could be explored for broader applications against bacterial infections.

The antiviral potential of Angelicin is also an area of active research. While its effectiveness may vary depending on the specific virus, Angelicin has shown activity against certain viruses. Early research indicated its ability to interfere with viral genome replication and gene expression, thereby inhibiting viral propagation. For instance, studies have explored its effects on gammaherpesviruses, showing it can downregulate viral replication and protein expression.

The dual action of Angelicin against both bacteria and viruses underscores its versatility as a natural therapeutic agent. NINGBO INNO PHARMCHEM CO.,LTD. is committed to further research in this domain, aiming to unlock the full potential of Angelicin in developing novel treatments for infectious diseases. The ongoing exploration of these properties could lead to significant advancements in public health and the fight against microbial and viral threats.